Is Hanshang Group Co., Ltd.'s (SHSE:600774) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Most readers would already be aware that Hanshang Group's (SHSE:600774) stock increased significantly by 58% over the past three months. We wonder if and what role the company's financials play in t

Simply Wall StMay 9 19:32 ET

Gelonghui Announcements Selected | HuaTest Navigation: The actual controller's concerted actions plan to increase the company's shares by 120 million yuan to 200 million yuan; Hanshang Group: Currently not developing stem cell treatment business

[Hot Focus] Hanshang Group (600774.SH): Currently not operating stem cell treatment business Hanshang Group (600774.SH) announced abnormal stock trading fluctuations, and the company is not currently engaged in stem cell treatment business. The company's Wuhan Huake Reproductive Specialist Hospital was awarded the “Hubei Engineering Research Center for Human Stem Cell Preparation and Application and Resource Preservation”. Currently, it is in the early stages of research and development, and no clinical application has been carried out. There have been no major changes in the company's main business, and there have been no major changes in fundamentals. Xinghu Technology (600866.SH): Shareholders Yipin Group and Tie Xiaorong reduced their total holdings

Gelonghui FinanceMay 9 09:48 ET

Hanshang Group (600774.SH) announced its 2023 annual results. Net profit of 61.2064 million yuan decreased by 32.24% year on year

According to Zhitong Finance App, Hanshang Group (600774.SH) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 1.39 billion yuan, an increase of 0.19%; net profit attributable to shareholders of listed companies was 61.2064 million yuan, a year-on-year decrease of 32.24%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376.931 million yuan, a year-on-year decrease of 15.67%; and basic earnings per share were 0.2075 yuan.

Zhitong FinanceApr 25 07:10 ET

Hanshang Group (600774.SH): Received 17.88 million yuan in government subsidies

Gelonghui, April 22丨Hanshang Group (600774.SH) announced that the company and its affiliated enterprises received a total of 17,882,339.82 yuan in government subsidies between August 29, 2023 and the date of publication of this announcement. Among them, the income-related subsidy was RMB 15,902,339.82, accounting for 17.97% of the company's most recent audited net profit attributable to shareholders of the listed company; the asset-related subsidy was RMB 1,980,000.00, accounting for 0.12% of the company's most recent audited net assets.

Gelonghui FinanceApr 22 03:43 ET

Hanshang Group (600774.SH): No participation or use of AI

Gelonghui, March 27丨Hanshang Group (600774.SH) said on an interactive platform that the company is currently not participating in or using AI.

Gelonghui FinanceMar 27 05:19 ET

Hanshang Group (600774.SH): Currently does not produce or sell atropine related pharmaceutical products

Gelonghui, March 27丨Hanshang Group (600774.SH) said on an interactive platform that its holding subsidiary Chongqing Dikang Changjiang Pharmaceutical Co., Ltd. holds atropine-related drug approvals (Sinopharm H50020864, Sinopharm H50020865, Sinopharm H50020866), but currently does not produce or sell atropine related pharmaceutical products.

Gelonghui FinanceMar 27 05:16 ET